Andrew Wiemer, Ph.D.

Dr. Andrew J. Wiemer works as a Professor in the Department of Pharmaceutical Sciences at the University of Connecticut. His research focuses on cancer immunology, integrating molecular mechanisms, metabolic pathways, and therapeutic design to guide the discovery of next-generation immunotherapies. He is most known for his foundational work on the butyrophilin family of immune receptors and their impact on T cell functions. He previously earned his B.S. in Biology from Notre Dame, completed a Ph.D. in Molecular Biology at Iowa focusing on anti-cancer therapies, and did postdoctoral research at Wisconsin–Madison on immune cell activation. His work has been supported by the NIH, the American Cancer Society, the American Association of Immunologists, the American Association of Colleges of Pharmacy, and the Frasch Foundation for Chemical Research.